FULVESTRANT + Exemestane for neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 May 2025: Trial registered, NCT06979596
  2. 11 Aug 2025: Trial started, NCT06979596

The trials

NCT06979596: A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

State
Under way
Phase
Phase 2
People
250 planned
Started
11 Aug 2025
Primary completion
4 Nov 2027
Arms
Fulvestrant or Exemestane
Results
None posted
  1. 20 May 2025: Trial registered
  2. 11 Aug 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.